ORHub, Inc. Acquires PUR Biologics, LLC

MilliporeSigma (Merck KGaA) to Acquire HUB Organoids Holding B.V.

December 17, 2024

Healthcare Services

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, has signed a definitive agreement to acquire HUB Organoids Holding B.V. (HUB). HUB develops organoid cell culture models and related services, with capabilities spanning model generation, assay development, and high-throughput screening to support drug discovery and development.

InVita Healthcare Technologies / The Riverside Company Acquire BloodHub

October 6, 2022

Cloud & SaaS

InVita Healthcare Technologies, a portfolio company of The Riverside Company, has acquired BloodHub and folded it into InVita's Blood Management Division. Riverside made the investment as an add-on to its InVita platform to expand InVita's blood- and biologics-focused supply chain and laboratory software capabilities across North America.

EmergentMedTech Merges with TRU Biologix

January 22, 2025

Biotechnology

EmergentMedTech announced a merger with TRU Biologix to integrate TRU Biologix's Wharton's Jelly–derived cell and tissue biologics into EmergentMedTech's regenerative medicine and aesthetics product portfolio. The deal expands EmergentMedTech's capabilities alongside its role as the exclusive U.S. distributor of NeoGen PSR, enabling delivery of advanced biologics to hundreds of clinics and clinician partners.

Young Innovations Acquires PuraGraft

November 11, 2019

Dental

Young Innovations, a portfolio company of The Jordan Company, has acquired PuraGraft, LLC, a Kingwood, Texas-based supplier of biomaterial solutions for bone and tissue regeneration and dental surgical supplies. The acquisition will expand Young Innovations' specialty dental product portfolio and support national distribution of PuraGraft's regenerative products, pharmaceuticals and related supplies.

Cyrus Biotechnology Acquires Orthogonal Biologics and Raises $18M Series B

December 6, 2021

Biotechnology

Cyrus Biotechnology completed an acquisition of Orthogonal Biologics and closed an $18 million Series B financing to build an integrated software-and-screening pre-clinical biologics discovery firm. The financing was led by a syndicate including OrbiMed Advisors, Trinity Ventures, Agent Capital and other investors, with Selecta Bioscience joining as a strategic investor; the acquisition brings Orthogonal’s deep mutational scanning protein engineering capabilities into Cyrus’s computational discovery platform.

Pharmaron Acquires 82.54% of Biortus Biosciences

October 28, 2025

Healthcare Services

Pharmaron Beijing Co., Limited has entered into a definitive Share Purchase Agreement to acquire 82.54% of Biortus Biosciences Co., Ltd. and its affiliates. The transaction is expected to close after satisfaction of customary closing conditions and is intended to strengthen Pharmaron’s structure-based drug discovery and protein science capabilities.